Emergent Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EMERGENT, and when can generic versions of EMERGENT drugs launch?
EMERGENT has three approved drugs.
There are seven US patents protecting EMERGENT drugs.
There are seventy-three patent family members on EMERGENT drugs in nineteen countries and one supplementary protection certificate in one country.
Drugs and US Patents for Emergent
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Emergent Biodefense | TEMBEXA | brincidofovir | SUSPENSION;ORAL | 214460-001 | Jun 4, 2021 | RX | Yes | Yes | 9,303,051 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Emergent Biodefense | TEMBEXA | brincidofovir | TABLET;ORAL | 214461-001 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
Emergent Biodefense | TEMBEXA | brincidofovir | SUSPENSION;ORAL | 214460-001 | Jun 4, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
Emergent | NARCAN | naloxone hydrochloride | SPRAY, METERED;NASAL | 208411-002 | Jan 24, 2017 | DISCN | Yes | No | 9,480,644 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Emergent Biodefense | TEMBEXA | brincidofovir | TABLET;ORAL | 214461-001 | Jun 4, 2021 | RX | Yes | Yes | 10,112,909 | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for EMERGENT drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Nasal Spray | 4 mg/spray | ➤ Subscribe | 2016-07-15 |
International Patents for Emergent Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Russian Federation | 2013114370 | ⤷ Subscribe |
China | 110755372 | ⤷ Subscribe |
European Patent Office | 2999476 | ⤷ Subscribe |
China | 105218580 | ⤷ Subscribe |
Russian Federation | 2015141024 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Emergent Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1685839 | 92292 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.